PierianDx Launches NGS Gateway Program
New Service Accelerates Personalized Medicine Initiatives for Healthcare Providers
ST. LOUIS--(BUSINESS WIRE)--PierianDx, the forerunner in clinical genomic informatics, announced the PDX NGS Gateway Program, a service designed to enable partner personalized medicine initiatives.
“No matter what stage of development their personalized medicine initiatives are in, this program provides the flexibility and support needed to accelerate NGS initiatives.”
PierianDx CEO Ted Briscoe said the NGS Gateway Program was developed in direct response to feedback from customers based on the growth of personalized medicine efforts across the country.
“There is no better way to help our partners realize the potential of personalized medicine than to offer a program like NGS Gateway,” said Briscoe. “No matter what stage of development their personalized medicine initiatives are in, this program provides the flexibility and support needed to accelerate NGS initiatives.”
With the NGS Gateway Program, PierianDx can partner with health systems, children’s hospitals, cancer centers and reference labs to easily implement any of the following components:
- Sequencing Services (DNA Preparation and Sequencing)
- Analytics and Reporting
- Medical Review and Sign-Out
The program is designed to complement PierianDx partners’ in-house NGS testing services, said Briscoe. The NGS Gateway Program was created to provide a range of “bridge” services for partners that are ramping internal capabilities. On short-term basis, PierianDx can provide sequencing and medical professional services in addition to its core analytic, interpretation, and reporting platform.
The NGS Gateway Program offers clinical labs an outsourced option to enhance their clinical offering with minimal capital commitment while transitioning to a more comprehensive internal solution.
Four gene set tests are currently offered through the NGS Gateway Program – solid tumor, hematopoietic disorders, CNS tumors and melanoma. All tests are conducted in a CAP-accredited, CLIA-certified lab. PierianDx can work with partners to customize assays to complement their existing offering and testing roadmap.
About PierianDx
PierianDx enables clinical labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In use since 2011, and regularly enhanced with new patient, clinical and research data, PierianDx’s proprietary Clinical Genomicist Workstation software provides clinical labs everything they need to manage their next-generation sequencing processes. For more information, please visit www.pieriandx.com or @PierianDx on Twitter.